Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis

BACKGROUND: Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated damage at the neuromuscular junction. Recently, the REGAIN study showed that eculizumab was effective and well tolerated in patients with anti-acetylcholine receptor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ther Adv Neurol Disord
Main Authors: Oyama, Munenori, Okada, Kensuke, Masuda, Masayuki, Shimizu, Yuko, Yokoyama, Kazumasa, Uzawa, Akiyuki, Kawaguchi, Naoki, Ikeguchi, Ryotaro, Hoshino, Yasunobu, Hatano, Taku, Ozawa, Yukiko, Nakahara, Jin, Aizawa, Hitoshi, Kitagawa, Kazuo, Hattori, Nobutaka, Kuwabara, Satoshi, Murai, Hiroyuki, Suzuki, Shigeaki
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2020
Assuntos:
Autoimmune Neurology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7081459/
https://ncbi.nlm.nih.gov/pubmed/32215054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420904207
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares